This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huber, B. E. Articles by Richards, C. A. Search for Related Content PubMed PubMed Citation Articles by Huber, B. E. Articles by Richards, C. A.

In Vivo Antitumor Activity of 5-Fluorocytosine on Human Colorectal Carcinoma Cells Genetically Modified to Express Cytosine Deaminase

Divisions of Cell Biology [B. E. H., E. A. A., V. C. K., C. A. R.] and Experimental Therapy [S. S. G., S. T.], Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709

¹ To whom requests for reprints should be addressed, at Wellcome Research Laboratories, 3030 Cornwallis Road, Research Triangle Park, NC 27709.

A human colorectal carcinoma cell line, WiDr, was genetically engineered to express the nonmammalian enzyme, cytosine deaminase (CD). Expression of CD in WiDr cells (WiDr/CD) did not alter the growth rate of these cells when grown in vitro or as solid tumor xenografts in nude mice. However, expression of CD did increase the sensitivity of these cells to the nontoxic prodrug, 5-fluorocytosine (FCyt), decreasing the 50% inhibitory concentration for FCyt from 26,000 µM in parental WiDr cells to 27 µM in WiDr/CD cells. The increase in sensitivity to FCyt in WiDr/CD cells was the result of the CD-mediated conversion of FCyt to 5-fluorouracil (FUra) and subsequent FUra anabolites. The half-life of the prodrug, FCyt, was determined to be approximately 40 min in nude mice. A single i.p. injection of 500 mg FCyt/kg body weight resulted in a transient FCyt plasma level of approximately 4000 µM while osmotic minipumps or constant tail vein infusions of FCyt achieved continual FCyt plasma levels of 5 µM and 50 µM, respectively, with no overt signs of toxicity. Significant antitumor effects were observed in nude mice bearing tumors derived from WiDr/CD cells when these animals were given 500 mg FCyt/kg i.p. for 10 consecutive days. These antitumor effects were demonstrated by decreases in tumor growth rate, tumor size, tumor weight, and thymidine incorporation into tumor DNA. This antitumor effect was significant but less profound if FCyt was administered by constant tail vein infusion. WiDr and WiDr/CD cells were very sensitive to FUra in vitro (50% inhibitory concentration approximately 5 /am). However, no significant antitumor effects were observed in nude mice bearing tumors derived from either WiDr or WiDr/CD cells when these animals were treated with various doses of FUra. Taken collectively, these data indicate that nontoxic plasma levels of FCyt can be attained which can produce profound antitumor effects on tumors engineered to express CD and that these antitumor effects are significantly better than those that can be achieved using FUra. These positive data support the continued development of a gene therapy approach to colorectal carcinoma involving the selective expression of CD in colorectal tumors with subsequent administration of FCyt.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 5/14/93. Accepted 8/17/93.

This article has been cited by other articles:

				F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al. Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation Blood, June 1, 2007; 109(11): 4698 - 4707. [Abstract] [Full Text] [PDF]

				G.-S. Shieh, A.-L. Shiau, Y.-T. Yo, P.-R. Lin, C.-C. Chang, T.-S. Tzai, and C.-L. Wu Low-Dose Etoposide Enhances Telomerase-Dependent Adenovirus-Mediated Cytosine Deaminase Gene Therapy through Augmentation of Adenoviral Infection and Transgene Expression in a Syngeneic Bladder Tumor Model. Cancer Res., October 15, 2006; 66(20): 9957 - 9966. [Abstract] [Full Text] [PDF]

				P. D. Boucher, M. M. Im, S. O. Freytag, and D. S. Shewach A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res., March 15, 2006; 66(6): 3230 - 3237. [Abstract] [Full Text] [PDF]

				S. D. Mahan, G. C. Ireton, C. Knoeber, B. L. Stoddard, and M. E. Black Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy Protein Eng. Des. Sel., August 1, 2004; 17(8): 625 - 633. [Abstract] [Full Text] [PDF]

				D. J. Waxman and P. S. Schwartz Harnessing Apoptosis for Improved Anticancer Gene Therapy Cancer Res., December 15, 2003; 63(24): 8563 - 8572. [Abstract] [Full Text] [PDF]

				P. Cejka, G. Marra, C. Hemmerle, E. Cannavo, Z. Storchova, and J. Jiricny Differential Killing of Mismatch Repair-Deficient and -Proficient Cells: Towards the Therapy of Tumors with Microsatellite Instability Cancer Res., December 1, 2003; 63(23): 8113 - 8117. [Abstract] [Full Text] [PDF]

				J. I. Grove, A. L. Lovering, C. Guise, P. R. Race, C. J. Wrighton, S. A. White, E. I. Hyde, and P. F. Searle Generation of Escherichia Coli Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB1954 Cancer Res., September 1, 2003; 63(17): 5532 - 5537. [Abstract] [Full Text] [PDF]

				Y.-C. Lin-Lee, S. Nakamura, V. Gandhi, S. A. Curley, D. Stuber, T. R. Burkot, and M. Tien Kuo Prolonged Stability and Sustained Prodrug Cell Killing Activity Using Receptor-mediated Delivery of Malarial Circumsporozoite-Cytosine Deaminase Fusion Protein into Liver Cancer Cells Mol. Cancer Ther., May 1, 2002; 1(7): 461 - 467. [Abstract] [Full Text] [PDF]

				D. C. Thomis, S. Marktel, C. Bonini, C. Traversari, M. Gilman, C. Bordignon, and T. Clackson A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease Blood, March 1, 2001; 97(5): 1249 - 1257. [Abstract] [Full Text] [PDF]

				H. Kanyama, N. Tomita, T. Yamano, T. Aihara, Y. Miyoshi, M. Ohue, M. Sekimoto, I. Sakita, Y. Tamaki, Y. Kaneda, et al. Usefulness of Repeated Direct Intratumoral Gene Transfer Using Hemagglutinating Virus of Japan-Liposome Method for Cytosine Deaminase Suicide Gene Therapy Cancer Res., January 1, 2001; 61(1): 14 - 18. [Abstract] [Full Text]

				P. Erbs, E. Regulier, J. Kintz, P. Leroy, Y. Poitevin, F. Exinger, R. Jund, and M. Mehtali In Vivo Cancer Gene Therapy by Adenovirus-mediated Transfer of a Bifunctional Yeast Cytosine Deaminase/Uracil Phosphoribosyltransferase Fusion Gene Cancer Res., July 1, 2000; 60(14): 3813 - 3822. [Abstract] [Full Text]

				V. Pierrefite-Carle, P. Baque, A. Gavelli, M. Mala, M. Chazal, J. Gugenheim, A. Bourgeon, G. Milano, P. Staccini, and B. Rossi Cytosine Deaminase/5-Fluorocytosine-Based Vaccination Against Liver Tumors: Evidence of Distant Bystander Effect J Natl Cancer Inst, December 1, 1999; 91(23): 2014 - 2019. [Abstract] [Full Text] [PDF]

				Y. Xie, J. D. Gilbert, J. H. Kim, and S. O. Freytag Efficacy of Adenovirus-mediated CD/5-FC and HSV-1 Thymidine Kinase/Ganciclovir Suicide Gene Therapies Concomitant with p53 Gene Therapy Clin. Cancer Res., December 1, 1999; 5(12): 4224 - 4232. [Abstract] [Full Text] [PDF]

				O. Wildner, R. M. Blaese, and F. Candotti Enzyme Prodrug Gene Therapy: Synergistic Use of the Herpes Simplex Virus-Cellular Thymidine Kinase/Ganciclovir System and Thymidylate Synthase Inhibitors for the Treatment of Colon Cancer Cancer Res., October 1, 1999; 59(20): 5233 - 5238. [Abstract] [Full Text] [PDF]

				L. D. Stegman, A. Rehemtulla, B. Beattie, E. Kievit, T. S. Lawrence, R. G. Blasberg, J. G. Tjuvajev, and B. D. Ross Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy PNAS, August 17, 1999; 96(17): 9821 - 9826. [Abstract] [Full Text] [PDF]

				H. S. Pandha, L.-A. Martin, A. Rigg, H. C. Hurst, G. W.H. Stamp, K. Sikora, and N. R. Lemoine Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of erbB-2-Directed Suicide Gene Expression J. Clin. Oncol., July 1, 1999; 17(7): 2180 - 2180. [Abstract] [Full Text] [PDF]

				M. F. X. Gnant, M. Puhlmann, H. R. Alexander Jr., and D. L. Bartlett Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice Cancer Res., July 1, 1999; 59(14): 3396 - 3403. [Abstract] [Full Text] [PDF]

				E. Kievit, E. Bershad, E. Ng, P. Sethna, I. Dev, T. S. Lawrence, and A. Rehemtulla Superiority of Yeast over Bacterial Cytosine Deaminase for Enzyme/Prodrug Gene Therapy in Colon Cancer Xenografts Cancer Res., April 1, 1999; 59(7): 1417 - 1421. [Abstract] [Full Text] [PDF]

				B. A. Bunnell and R. A. Morgan Gene Therapy for Infectious Diseases Clin. Microbiol. Rev., January 1, 1998; 11(1): 42 - 56. [Abstract] [Full Text] [PDF]

				R. L. Harrell, M. A. S. Rajanayagam, A. M. Doanes, R. J. Guzman, E. A. Hirschowitz, R. G. Crystal, S. E. Epstein, and T. Finkel Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Accumulation by Adenovirus-Mediated Gene Transfer of Cytosine Deaminase Circulation, July 15, 1997; 96(2): 621 - 627. [Abstract] [Full Text]

				K. Wei and B. E. Huber Cytosine Deaminase Gene as a Positive Selection Marker J. Biol. Chem., February 16, 1996; 271(7): 3812 - 3816. [Abstract] [Full Text] [PDF]